Aesthetic & Anti-Ageing treatment options (2026): standard, alternative & regenerative
Products marketed for skin, hair or systemic rejuvenation may contain or claim to contain adipose-derived cells, stromal vascular fraction, placental or amniotic material, conditioned media or exosomes. These are not one intervention. A laboratory claim about collagen, inflammation or signalling does not establish a visible, durable clinical benefit or product safety.
Standard & first-line treatment for Aesthetic & Anti-Ageing
Established care should follow a diagnosis-specific plan made with a suitably qualified clinician. Depending on the condition, that plan may include cause-directed treatment, authorised medicines or procedures, rehabilitation, monitoring and supportive care. Selection depends on severity, other illnesses, current medicines, contraindications and the person's goals. An experimental product must not displace urgent or time-sensitive established care.
Alternative & complementary options
Complementary approaches are not interchangeable with established treatment. Evidence, product quality, interactions and practitioner regulation differ by method and condition. Ask what outcome was studied, in which population, against which comparator and for how long. Discuss supplements, devices and procedures with the treating team, and do not use testimonials or a package label as evidence of benefit.
Regenerative and cell interventions: evidence and regulatory status
Evidence must match the exact composition, manufacturing, route, anatomical site, comparator, validated patient-reported or blinded aesthetic outcome and follow-up. The FDA safety alert on unapproved stem-cell and exosome products states that there are no FDA-approved exosome products and describes serious adverse events. A before-and-after photograph, ingredient label or clinic testimonial is not a controlled study. Treat this as product-specific research, not as a generic treatment class. Verify the exact product, source, processing, manufacturer, dose, route, indication, regulator or ethics approval, comparator, endpoints and adverse-event plan. See the condition evidence page for registry and study context.
Aesthetic & Anti-Ageing treatment options compared
| Option | Type | Evidence | Cost information | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Diagnostic and specialist assessment | Standard | Required to define diagnosis, cause, severity and suitability | Varies by tests, country, coverage and provider; request an itemised quote | Depends on the assessment | No universal timeline |
| Guideline-directed established care | Standard | Condition- and patient-specific; use the current clinical guideline | Varies by treatment, country and coverage; request an itemised quote | Depends on the selected treatment | Defined by the selected established treatment |
| Rehabilitation, monitoring and supportive care | Standard / supportive | Condition- and goal-specific | Varies by programme, duration, country and coverage | Usually low, but programme-specific | Ongoing and goal-specific |
| Cell, exosome or other regenerative intervention | Authorised clinical trial only / research | Investigational; exact product and indication must be verified | A commercial price is not evidence of approval, safety or efficacy | Depends on collection, processing and administration | Defined by the authorised protocol; benefit is uncertain |
Aesthetic & Anti-Ageing treatment — common questions
How should established options be selected?
Start with a confirmed diagnosis and an independent clinician who can apply the current condition-specific guideline. Compare expected benefits, harms, burden, alternatives and what happens without treatment. Choice cannot be reduced to a universal ranking or a commercial package.
Is a regenerative product approved for this condition?
There are no FDA-approved exosome products. A device clearance, cosmetic registration, tissue-bank status or approval of another product does not authorise an injected or topical biological product for rejuvenation; verify the exact jurisdiction and use.
How should cost and value be assessed?
Request an itemised quote naming product, manufacturer, dose, route, number of sessions, anaesthesia, follow-up and management of infection, scarring, pigmentation, vascular injury or other complications. Compare it with authorised dermatological or surgical options and do not finance repeat sessions on an assumed maintenance schedule. Elective aesthetic procedures and their complications may be treated differently by each policy. Obtain written coverage information for the exact intervention and complication care; do not assume a clinic package or travel policy covers it. Outside an authorised study or authorised product use, evidence may not justify the cost and biological risk of a cell or exosome procedure for aesthetic goals. An independent specialist should compare less invasive established options and clarify realistic endpoints.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Aesthetic & Anti-Ageing (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
- Clinic perspective — Stem Plus on Aesthetic & Anti-Ageing ↗
Educational overview only; not medical advice. Verify current guidance, regulatory status and treatment options with the cited authorities and an independent qualified physician.